RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Adamis Pharmaceuticals Stock

Adamis Pharmaceuticals Revenue 2024

Adamis Pharmaceuticals Revenue

35.07 M USD

Ticker

ADMP

ISIN

US00547W2089

WKN

A1XA2F

In 2024, Adamis Pharmaceuticals's sales reached 35.07 M USD, a 100.08% difference from the 17.53 M USD sales recorded in the previous year.

The Adamis Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2026e148.02-0,97
2025e71.34-2,01
2024e35.07-4,08
2023e17.53-8,17
20224.76-30,10
20212.21-211,14
20202.78-127,87
201922.1130,03
201815.0935,06
201713.0743,23
20166.4725,04
2015--
2014--
2013--
2012--
2011--
2010--
20090.2910,34
2008--
2007--
20062.6690,23
200512.297,95
20042.0397,04
20031.6288,27

Adamis Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Adamis Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Adamis Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Adamis Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Adamis Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Adamis Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Adamis Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Adamis Pharmaceuticals’s growth potential.

Adamis Pharmaceuticals Revenue, EBIT and net profit per share

DateAdamis Pharmaceuticals RevenueAdamis Pharmaceuticals EBITAdamis Pharmaceuticals Net Income
2026e148.02 M undefined2.12 M undefined1.97 M undefined
2025e71.34 M undefined3.75 M undefined3.43 M undefined
2024e35.07 M undefined6.75 M undefined6.12 M undefined
2023e17.53 M undefined-10.54 M undefined-7.65 M undefined
20224.76 M undefined-25.06 M undefined-26.48 M undefined
20212.21 M undefined-32.07 M undefined-45.83 M undefined
20202.78 M undefined-31.68 M undefined-49.39 M undefined
201922.11 M undefined-29.03 M undefined-27.51 M undefined
201815.09 M undefined-39.45 M undefined-39.01 M undefined
201713.07 M undefined-24.69 M undefined-25.54 M undefined
20166.47 M undefined-25.2 M undefined-20.81 M undefined
20150 undefined-13.85 M undefined-13.57 M undefined
20140 undefined-8.1 M undefined-9.32 M undefined
20130 undefined-4.4 M undefined-8.16 M undefined
20120 undefined-3.22 M undefined-7.19 M undefined
20110 undefined-4.82 M undefined-4.92 M undefined
20100 undefined-6.24 M undefined-6.98 M undefined
2009290,000 undefined-3.98 M undefined-6.71 M undefined
20080 undefined-1.32 M undefined-1.53 M undefined
20070 undefined-1.83 M undefined-1.93 M undefined
20062.66 M undefined-4.68 M undefined9.67 M undefined
200512.2 M undefined-5.36 M undefined-5.01 M undefined
20042.03 M undefined-14 M undefined-28.15 M undefined
20031.62 M undefined-13.89 M undefined-13.53 M undefined

Adamis Pharmaceuticals stock margins

The Adamis Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Adamis Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Adamis Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Adamis Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Adamis Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Adamis Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Adamis Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Adamis Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Adamis Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Adamis Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Adamis Pharmaceuticals Margin History

Adamis Pharmaceuticals Gross marginAdamis Pharmaceuticals Profit marginAdamis Pharmaceuticals EBIT marginAdamis Pharmaceuticals Profit margin
2026e-30.1 %1.43 %1.33 %
2025e-30.1 %5.25 %4.81 %
2024e-30.1 %19.26 %17.45 %
2023e-30.1 %-60.14 %-43.64 %
2022-30.1 %-526.88 %-556.72 %
2021-211.14 %-1,451.97 %-2,074.91 %
2020-127.87 %-1,140.96 %-1,778.84 %
201930.03 %-131.3 %-124.42 %
201835.06 %-261.43 %-258.52 %
201743.23 %-188.91 %-195.41 %
201625.04 %-389.49 %-321.64 %
2015-30.1 %0 %0 %
2014-30.1 %0 %0 %
2013-30.1 %0 %0 %
2012-30.1 %0 %0 %
2011-30.1 %0 %0 %
2010-30.1 %0 %0 %
200910.34 %-1,372.41 %-2,313.79 %
2008-30.1 %0 %0 %
2007-30.1 %0 %0 %
200690.23 %-175.94 %363.53 %
200597.95 %-43.93 %-41.07 %
200497.04 %-689.66 %-1,386.7 %
200388.27 %-857.41 %-835.19 %

Adamis Pharmaceuticals Aktienanalyse

What does Adamis Pharmaceuticals do?

Adamis Pharmaceuticals Corp is a biotechnology company based in the USA that specializes in the development of pharmaceuticals and medical devices. The company was founded in 2006 and is headquartered in San Diego, California. History: Adamis Pharmaceuticals was founded by Dr. Dennis J. Carlo, an experienced pharmaceutical executive with over 35 years of industry experience. The company initially focused on the development of therapeutics for the treatment of allergies and respiratory diseases. Over the years, the company has expanded its portfolio and specialized in the development of drugs for the treatment of anaphylaxis, asthma, and prostate cancer, as well as medical devices for drug delivery. Business model: Adamis Pharmaceuticals focuses on the development of novel drugs and medical devices that can improve patients' lives. The company seeks opportunities to meet unmet medical needs in existing therapy areas. Adamis collaborates closely with leading medical institutions and research facilities to develop and market a portfolio of innovative products. Various divisions: The company has various divisions, including: 1. Allergy/Respiratory: Adamis Pharmaceuticals has developed a broad portfolio of therapeutic agents for the treatment of allergies and respiratory diseases. The company has also developed a patented device called Symjepi, which is used to treat anaphylaxis, a life-threatening allergic reaction. This device also allows untrained individuals to self-treat in an anaphylaxis situation. 2. Oncology: Adamis Pharmaceuticals has developed a novel drug called TeloBlast®, which is used to treat prostate cancer. TeloBlast® targets telomerase, which is upregulated in many types of cancer. The company intends to develop additional drugs for the treatment of cancer in the future. 3. CNS: Adamis Pharmaceuticals has also developed innovative drugs for the treatment of CNS (central nervous system) disorders. The company plans to bring several new drugs for the treatment of neurological disorders to the market by 2022. 4. Medical devices: Adamis Pharmaceuticals has developed a range of patented medical devices, including the ZIM high-pressure injection pump, which allows doctors and nurses to administer medications quickly and accurately. Products: Adamis Pharmaceuticals' products include: 1. Symjepi: A patented device for the treatment of anaphylaxis. 2. TeloBlast®: A novel drug for the treatment of prostate cancer. 3. ZIM high-pressure injection pump: A patented medical device for drug administration. 4. Fluticasone/Salmeterol: An inhalable combination drug for the treatment of asthma and COPD (chronic obstructive pulmonary disease). Adamis Pharmaceuticals is an innovative biotechnology company specializing in the development of pharmaceuticals and medical devices. The company aims to meet unmet medical needs and improve patients' lives. With a broad portfolio of products and a strong commitment to research and development, Adamis Pharmaceuticals is well positioned to continue growing in the future. Adamis Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Adamis Pharmaceuticals's Sales Figures

The sales figures of Adamis Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Adamis Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Adamis Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Adamis Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Adamis Pharmaceuticals stock

How much revenue did Adamis Pharmaceuticals generate this year?

Adamis Pharmaceuticals has achieved a revenue of 35.07 M USD this year.

How much was the turnover of the company Adamis Pharmaceuticals compared to the previous year?

The revenue of Adamis Pharmaceuticals has increased by 100.08% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Adamis Pharmaceuticals?

The revenue of Adamis Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Adamis Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Adamis Pharmaceuticals so important for investors?

The revenue of Adamis Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Adamis Pharmaceuticals pay?

Over the past 12 months, Adamis Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adamis Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Adamis Pharmaceuticals?

The current dividend yield of Adamis Pharmaceuticals is .

When does Adamis Pharmaceuticals pay dividends?

Adamis Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adamis Pharmaceuticals?

Adamis Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Adamis Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adamis Pharmaceuticals located?

Adamis Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adamis Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adamis Pharmaceuticals from 10/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/10/2024.

When did Adamis Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/10/2024.

What was the dividend of Adamis Pharmaceuticals in the year 2023?

In the year 2023, Adamis Pharmaceuticals distributed 0 USD as dividends.

In which currency does Adamis Pharmaceuticals pay out the dividend?

The dividends of Adamis Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Adamis Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Adamis Pharmaceuticals

Our stock analysis for Adamis Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adamis Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.